| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Eliem Therapeutics, Inc. | EVP, R&D AND CSO | Common Stock | 31,317 | $249,910 | $7.98 | 22 Jul 2024 | Direct |
| Eliem Therapeutics, Inc. | EVP, R&D AND CSO | Stock Option (Right to Buy) | 10,198 | 01 Jul 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CLYM | Eliem Therapeutics, Inc. | 19 Jul 2024 | 4 | -$988,495 | 4 | EVP, R&D AND CSO | 23 Jul 2024, 17:04 |
| CLYM | Eliem Therapeutics, Inc. | 17 Jul 2024 | 2 | -$289,492 | 4 | EVP, R&D AND CSO | 19 Jul 2024, 11:12 |
| CLYM | Eliem Therapeutics, Inc. | 16 Jul 2024 | 1 | -$356,500 | 4 | EVP, R&D AND CSO | 17 Jul 2024, 18:11 |
| CLYM | Eliem Therapeutics, Inc. | 12 Jul 2024 | 2 | -$650,563 | 4 | EVP, R&D AND CSO | 16 Jul 2024, 18:14 |
| CLYM | Eliem Therapeutics, Inc. | 09 Jul 2024 | 3 | -$736,500 | 4 | EVP, R&D AND CSO | 11 Jul 2024, 20:45 |
| CLYM | Eliem Therapeutics, Inc. | 05 Jul 2024 | 1 | -$87,135 | 4 | EVP, R&D AND CSO | 09 Jul 2024, 16:46 |
| CLYM | Eliem Therapeutics, Inc. | 01 Jul 2024 | 3 | -$337,998 | 4 | EVP, R&D AND CSO | 03 Jul 2024, 14:42 |
| CLYM | Eliem Therapeutics, Inc. | 05 Apr 2024 | 2 | +$3.57 | 4 | EVP, R&D AND CSO | 08 Apr 2024, 17:33 |
| CLYM | Eliem Therapeutics, Inc. | 20 Sep 2023 | 4 | +$13.92 | 4 | EVP, R&D AND CSO | 04 Mar 2024, 11:07 |
| CLYM | Eliem Therapeutics, Inc. | 10 Mar 2023 | 4 | +$523 | 4 | EVP, R&D and CSO | 14 Mar 2023, 17:04 |
| CLYM | Eliem Therapeutics, Inc. | 31 Oct 2022 | 1 | $0 | 4 | EVP, R&D and CSO | 02 Nov 2022, 19:11 |
| CLYM | Eliem Therapeutics, Inc. | 27 Jan 2022 | 1 | $0 | 4 | EVP, R&D and CSO | 31 Jan 2022, 16:11 |
| CLYM | Eliem Therapeutics, Inc. | 09 Aug 2021 | 0 | $0 | 3 | Chief Scientific Officer | 09 Aug 2021, 18:08 |